NOVOEIGHT Drug Profile

Summary for Tradename: NOVOEIGHT

High Confidence Patents:	10
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for NOVOEIGHT

Recent Clinical Trials for NOVOEIGHT

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Novo Nordisk A/S	Phase 1
Novo Nordisk A/S

See all NOVOEIGHT clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for NOVOEIGHT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for NOVOEIGHT Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOEIGHT	antihemophilic factor (recombinant)	For Injection	125466	6,100,061	2018-06-19	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOEIGHT	antihemophilic factor (recombinant)	For Injection	125466	6,475,725	2019-06-02	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOEIGHT	antihemophilic factor (recombinant)	For Injection	125466	6,936,441	2022-06-12	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOEIGHT	antihemophilic factor (recombinant)	For Injection	125466	7,094,574	2025-05-06	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOEIGHT	antihemophilic factor (recombinant)	For Injection	125466	8,080,414	2029-06-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for NOVOEIGHT Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOEIGHT	antihemophilic factor (recombinant)	For Injection	125466	6,248,363	2019-11-23	Patent claims search
Novo Nordisk Inc.	NOVOEIGHT	antihemophilic factor (recombinant)	For Injection	125466	6,309,663	2019-08-17	Patent claims search
Novo Nordisk Inc.	NOVOEIGHT	antihemophilic factor (recombinant)	For Injection	125466	6,720,001	2019-10-18	Patent claims search
Novo Nordisk Inc.	NOVOEIGHT	antihemophilic factor (recombinant)	For Injection	125466	9,700,486	2034-04-23	Patent claims search

International Patents for NOVOEIGHT

Country	Patent Number	Estimated Expiration
Austria	E540975
Russian Federation	2009143635
South Korea	101594805
Russian Federation	2477318
Poland	2167526

Supplementary Protection Certificates for NOVOEIGHT

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C300663	Netherlands		PRODUCT NAME: TUROCTOCOG ALFA, IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/13/888 20131113
132014902257593	Italy		PRODUCT NAME: TUROCTOCOG ALFA(NOVOEIGHT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/888, 20131113
14C0037	France		PRODUCT NAME: TUROCTOCOG ALFA; REGISTRATION NO/DATE: EU/1/13/888 20131113
122014000053	Germany		PRODUCT NAME: TUROCTOCOG ALFA; REGISTRATION NO/DATE: EU/1/13/888 20131113
1490031-0	Sweden		PRODUCT NAME: TUROKTOKOG ALFA; REG. NO/DATE: EU/1/13/888 20131113

Market Dynamics and Financial Trajectory for NOVOEIGHT: A Comprehensive Analysis

Last updated: September 23, 2025

---

Introduction

NOVOEIGHT, a biosimilar pharmaceutical product targeting hemophilia A, emerges within a rapidly evolving biomedical landscape emphasizing affordability and expanded patient access. As a recombinant factor VIII (FVIII) biosimilar, NOVOEIGHT addresses a significant unmet need in hemophilia management, promising substantial market penetration. This article evaluates the current market dynamics and projects the financial trajectory for NOVOEIGHT, considering competitive pressures, regulatory pathways, market access, and global adoption trends.

---

Market Landscape for Hemophilia A Biologics

Hemophilia A is a hereditary bleeding disorder caused by FVIII deficiency, affecting approximately 1 in 5,000 male births globally [1]. Historically, treatment has relied heavily on recombinant FVIII products, often characterized by high costs—annual therapies can reach hundreds of thousands of dollars per patient—limiting access, especially in emerging markets.

The biosimilar segment is poised to transform this landscape. Since the expiration of patents for pioneer biologics like haemophilia treatments from companies such as Bayer, Bioverativ, and Shire (now part of Takeda), biosimilars like NOVOEIGHT have gained regulatory approval and entered markets predominantly structured by pricing pressures and healthcare cost containment initiatives.

---

Regulatory and Commercial Drivers

Regulatory Approval and Market Entry

In Europe, agencies such as the EMA have approved NOVOEIGHT as a biosimilar, aligning with stringent standards for biosimilarity, demonstrating similarity in safety, efficacy, and quality to the reference product. Similarly, the FDA's pathway for biosimilars under the BPCIA (Biologics Price Competition and Innovation Act) has established a framework that facilitates NOVOEIGHT’s potential entry into the North American market.

Pricing and Reimbursement

Biosimilars are primarily driven by price reductions—often 20-35% lower than originators—enhancing formulary placement and reimbursement prospects. Market access depends on measurable savings, stakeholder acceptance, and robust pharmacovigilance frameworks. Payers increasingly favor biosimilars to curb expenditures, creating a favorable environment for NOVOEIGHT's commercialization.

Clinical and Physician Adoption

Physician confidence hinges on robust clinical data and post-market safety records. Novoeight's clinical trials demonstrated comparable immunogenicity and safety profiles with reference products [2]. Additionally, education campaigns bolster clinician acceptance, vital for market penetration.

---

Competitive Landscape

The biosimilar hemophilia A space is highly competitive, featuring players such as Sobi’s Elocta and Bioverativ’s Afstyla, which are often categorized as recombinant products with distinct administration profiles. Novo Nordisk, Biogen, and other biotech firms continue advancing biosimilar pipelines, closely monitored by regulators and payers.

Market Differentiators

• Efficacy Similarity: Confirming biosimilar equivalence.
• Cost Advantage: Leading to increased adoption in price-sensitive markets.
• Delivery Formulations: Ease of use can influence clinician preference.

Potential Barriers

• Brand Loyalty: Established relations with original biologic manufacturers.
• Regulatory Variances: Variations in biosimilar acceptance among countries.
• Manufacturing and Supply Chain: Ensuring consistent product quality.

---

Global Market Trajectory

Market Size and Growth Expectations

The global hemophilia therapeutics market was valued at approximately USD 11 billion in 2022 and is projected to grow at a compounded annual growth rate (CAGR) of 5-7% through 2030 [3]. Biosimilars are anticipated to claim a significant share by the mid-2020s due to their competitive pricing.

Emerging Markets

While established markets like Europe and North America are early adopters, emerging markets in Asia-Pacific, Latin America, and Africa present lucrative growth opportunities for NOVOEIGHT. The cost sensitivity and expanding healthcare infrastructure in these regions position biosimilars as critical access solutions.

Reimbursement and Policy Trends

Government-led initiatives favor biosimilar uptake, including China’s Biosimilar Guidelines and India’s pricing regulations. Payer policies that favor biosimilar substitution underpin a steady increase in adoption rates globally.

Financial Outlook for NOVOEIGHT

Revenue Projections

Considering current approval status, anticipated market penetration, and price differentials, NOVOEIGHT’s revenue could grow from a modest initial baseline to hundreds of millions USD within five years of launch, depending on regional market penetration and competitive dynamics.

Profitability and Cost Considerations

Manufacturing efficiencies and economies of scale are pivotal. Initial R&D and regulatory costs are considerable, but with established biosimilar manufacturing frameworks, long-term margins are anticipated to be favorable—market prices for biosimilars tend to stabilize, and incremental sales volume drives profitability.

Strategic Expansion

Expanding indications, such as for pediatric or prophylactic use, and pursuing regulatory approvals in additional jurisdictions (e.g., Japan, Canada, Australia), will be instrumental in augmenting revenue streams.

---

Risks and Challenges

• Regulatory Hurdles: Stringent approvals and biogeneric equivalence testing requirements.
• Market Entry Barriers: Established clinician and patient loyalty to reference products.
• Pricing Pressures: Intense competition ultimately narrows profit margins.
• Supply Chain and Manufacturing Risks: Disruptions could impact market availability.

---

Conclusion

The market dynamics for NOVOEIGHT position it as a key player in the expanding biosimilar hemophilia A space. Regulatory acceptance, cost advantages, and increased global adoption underpin its revenue growth potential. Nonetheless, its financial trajectory will be shaped by competitive intensity, market access strategies, and regional health policy landscapes. If these factors are effectively navigated, NOVOEIGHT can achieve a sustainable and profitable footprint in the evolving hemophilia therapeutics market.

---

Key Takeaways

• Market Opportunity: Globally rising hemophilia prevalence and biosimilar acceptance present a significant growth opportunity.
• Strategic Focus: Success hinges on regulatory approval, physician confidence, and cost competitiveness.
• Financial Outlook: Revenue expansion to hundreds of millions USD over five years is plausible, driven by global adoption and multiple indications.
• Challenges to Address: Competition, reimbursement hurdles, and supply chain stability require proactive management.
• Policy Environment: Favorable regulatory and reimbursement trends in key markets bolster growth prospects.

---

FAQs

Q1: What factors influence the adoption of NOVOEIGHT in global markets?
A1: Factors include regulatory approvals, clinical confidence, reimbursement policies, cost competitiveness, and physician acceptance.

Q2: How does the pricing of NOVOEIGHT impact its market penetration?
A2: Competitive pricing, typically 20-35% lower than reference biologics, enhances formulary inclusion and patient accessibility, driving market share.

Q3: What are the primary regulatory pathways for NOVOEIGHT’s global expansion?
A3: The EMA (Europe), FDA (United States), and similar agencies in Japan, Canada, and Australia provide approval pathways based on biosimilarity data, with varying requirements.

Q4: What are the main risks associated with NOVOEIGHT’s financial growth?
A4: Risks include regulatory delays, strong competition from other biosimilars or originators, pricing pressures, and manufacturing disruptions.

Q5: How significant is NOVOEIGHT’s potential in emerging markets?
A5: Extremely significant, as price sensitivity and expanding healthcare infrastructure support biosimilar adoption, enabling broader access and higher sales volumes.

---

References

[1] World Federation of Hemophilia. Hemophilia Facts & Figures. 2022.

[2] European Medicines Agency. NovoEight Summary of Product Characteristics. 2021.

[3] Research and Markets. Hemophilia Therapeutics Market Size & Trends. 2022.